The panel based on these three miRNAs in combination with AFP levels significantly enhances the diagnostic surveillance of HCC in individuals with HBV-related liver diseases, especially in LC patients and HBV patients with normal AFP levels or HCC patients with small tumor sizes. The gene discussed is AFP; the disease is liver disorder.